Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

Douglas W. McMillin, Jake Delmore, Joseph M. Negri, Matthew Vanneman, Shohei Koyama, Robert L. Schlossman, Nikhil C. Munshi, Jacob Laubach, Paul G. Richardson, Glenn Dranoff, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2012) 119 (15): e131–e138.

https://doi.org/10.1182/blood-2011-04-348490

Published: 2012

Includes: Supplemental data

Journal Articles

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Jana Jakubikova, Sophia Adamia, Maria Kost-Alimova, Steffen Klippel, David Cervi, John F. Daley, Dana Cholujova, Sun-Young Kong, Merav Leiba, Simona Blotta, Melissa Ooi, Jake Delmore, Jacob Laubach, Paul G. Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2011) 117 (17): 4409–4419.

https://doi.org/10.1182/blood-2010-02-267344

Published: 2011

Includes: Supplemental data

Journal Articles

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Jana Jakubikova, PhD, Melissa Ooi, MD, Steffen Klippel, PhD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 5016.

https://doi.org/10.1182/blood.V116.21.5016.5016

Published: 2010

Journal Articles

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Efstathios Kastritis, Jana Jakubikova, Jake Delmore, Steffen Klippel, Douglas W. McMillin, Melissa Ooi, Hannah M. Jacobs, Jacob P. Laubach, Paul G Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1574.

https://doi.org/10.1182/blood.V116.21.1574.1574

Published: 2010

Journal Articles

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Jana Jakubikova, PhD, Steffen Klippel, PhD, Efstathios Kastritis, MD, John Daley, Melissa Ooi, MD, Jake Delmore, Jacob P. Laubach, MD, Paul G Richardson, MD, Jan Sedlak, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2010) 116 (21): 1581.

https://doi.org/10.1182/blood.V116.21.1581.1581

Published: 2010

Journal Articles

Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function

Douglas W. McMillin, Jake Delmore, Matthew W. Vanneman, Robert L. Schlossman, MD, John Feather, Nikhil C. Munshi, Jacob P. Laubach, Paul G Richardson, Glenn Dranoff, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2010) 116 (21): 451.

https://doi.org/10.1182/blood.V116.21.451.451

Published: 2010

Journal Articles

MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors

Douglas W. McMillin, Zachary Hunter, Jake Delmore, Val Monrose, Peter G Smith, Ann Birner, Paul G Richardson, Kenneth C. Anderson, Steven P. Treon, Andrew L. Kung, Constantine S. Mitsiades

Blood (2010) 116 (21): 2988.

https://doi.org/10.1182/blood.V116.21.2988.2988

Published: 2010

Journal Articles

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

Richard J. Rickles, Laura T. Pierce, Thomas P. Giordano, 3rd, Winnie F. Tam, Douglas W. McMillin, Jake Delmore, Jacob P. Laubach, Alexis A. Borisy, Paul G. Richardson, Margaret S. Lee

Blood (2010) 116 (4): 593–602.

https://doi.org/10.1182/blood-2009-11-252668

Published: 2010

Includes: Supplemental data

Journal Articles

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Melissa G Ooi, M.D., Robert O'Connor, Ph.D, Jana Jakubikova, Ph.D, Justine Meiller, Diploma, in, Biochemistry, Degre, Steffen Klippel, Ph.D, Jake Delmore, Efstathios Kastritis, M.D, Douglas McMillin, Ph.D, Martin Clynes, Ph.D, Paul Richardson, M.D., Constantine S. Mitsiades, M.D., Ph.D, Peter O'Gorman, M.D., Kenneth C. Anderson, M.D.

Blood (2009) 114 (22): 1729.

https://doi.org/10.1182/blood.V114.22.1729.1729

Published: 2009

Journal Articles

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

Steffen Klippel, Jana Jakubikova, Jake Delmore, Melissa G. Ooi, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2009) 114 (22): 1741.

https://doi.org/10.1182/blood.V114.22.1741.1741

Published: 2009

Journal Articles

Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.

Douglas McMillin, Jake Delmore, Ellen Weisberg, Joseph M. Negri, Steffen Klippel, Nicholas Mitsiades, Nikhil C. Munshi, James D Griffin, Paul G. Richardson, Kenneth C. Anderson, Andrew L. Kung, Constantine S. Mitsiades

Blood (2009) 114 (22): 1722.

https://doi.org/10.1182/blood.V114.22.1722.1722

Published: 2009

Journal Articles

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Jake Delmore, David N. Cervi, Douglas McMillin, Efstathios Kastritis, Jana Jakubikova, Melissa G. Ooi, Steffen Klippel, Joseph M. Negri, Leutz Buon, Jacob Laubach, Luca Rastelli, Ann Clark, Samantha M. Sarno, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 730.

https://doi.org/10.1182/blood.V114.22.730.730

Published: 2009

Journal Articles

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Jana Jakubikova, David N. Cervi, John F. Daley, Danka Cholujova, Melissa G. Ooi, Steffen Klippel, Simona Blotta, Merav Leiba, Jake Delmore, Douglas McMillin, Efstathios Kastritis, Jacob Laubach, Paul Richardson, Jan Sedlak, Kenneth C. Anderson, Constantine S. Mitsiades, M.D., Ph.D

Blood (2009) 114 (22): 954.

https://doi.org/10.1182/blood.V114.22.954.954

Published: 2009

Journal Articles

Effects of Tanespimycin On Glucocorticoid Receptor Translocation.

Constantine S. Mitsiades, MD, PhD, Michele Agler, YingJie Zhu, Melissa Ooi, Jake Delmore, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2009) 114 (22): 4921.

https://doi.org/10.1182/blood.V114.22.4921.4921

Published: 2009

Journal Articles

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Douglas W. McMillin, PhD, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Jana Jakubikova, Renee Wright, Nathanael Gray, PhD, Andrew Kung, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2764.

https://doi.org/10.1182/blood.V112.11.2764.2764

Published: 2008

Journal Articles

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

Melissa G. Ooi, Patrick J. Hayden, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Noopur S Raje, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2651.

https://doi.org/10.1182/blood.V112.11.2651.2651

Published: 2008

Journal Articles

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Nikhil C. Munshi, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Nicholas Mitsiades

Blood (2008) 112 (11): 2652.

https://doi.org/10.1182/blood.V112.11.2652.2652

Published: 2008

Journal Articles

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Douglas W. McMillin, PhD, Richard Rickles, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Melissa Farwell, David Crowe, Mei Chen, William Avery, Vikram Kansra, PhD, Kenneth C. Anderson, MD, Margaret S. Lee, PhD, Constantine S. Mitsiades, MD, PhD

Blood (2008) 112 (11): 2663.

https://doi.org/10.1182/blood.V112.11.2663.2663

Published: 2008

Journal Articles

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Steffen Klippel, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2008) 112 (11): 219.

https://doi.org/10.1182/blood.V112.11.219.219

Published: 2008

Journal Articles

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

Douglas W. McMillin, Joseph Negri, Jake Delmore, Patrick Hayden, Melissa Ooi, Nicholas Mitsiades, Robert Schlossman, Paul G. Richardson, Nikhil C. Munshi, Michael R. Jensen, Cornelia Quadt, Patrick Chène, Joseph Schoepfer, Carlos García-Echeverría, Kenneth C. Anderson, Constantine S. Mitsiades

Blood (2007) 110 (11): 1587.

https://doi.org/10.1182/blood.V110.11.1587.1587

Published: 2007

NARROW

Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications

Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions.

Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.

Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function

MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias.

Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells.

Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.

The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.

Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.

Effects of Tanespimycin On Glucocorticoid Receptor Translocation.

Activity of Plk Inhibitor BI2536 on Myeloma Cells

Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib

The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics

Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only